Aerius 5mg 10 tablets — Made in Belgium — Free Delivery

Product description

Aerius ® tablets are used to eliminate symptoms associated with:

• allergic rhinitis;
• hives.

Structure

The active ingredient is desloratadine (one tablet contains 5 mg of desloratadine).

Excipients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, corn starch, talc, carnauba wax, white wax; film shell: lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide (E 171), polyethylene glycol, indigo carmine (E 132); transparent shell: hydroxypropyl methylcellulose, polyethylene glycol.

Contraindications

Hypersensitivity to the active substance or to any auxiliary or to loratadine.

Mode of application

Adults and children over 12 years of age: one tablet once a day, regardless of food intake, to eliminate symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.

Therapy of intermittent allergic rhinitis (the presence of symptoms less than 4 days a week or less than 4 weeks) should be carried out taking into account the history data: stop after the symptoms disappear and restore after their reoccurrence.

With persistent allergic rhinitis (the presence of symptoms more than 4 days a week or more than 4 weeks), it is necessary to continue treatment during the entire period of contact with the allergen.

Application features

Pregnant

Desloratadine has not been shown to be teratogenic in animal studies. The safety of using the drug during pregnancy has not been established, therefore the use of the drug "Aerius ®" during this period is not recommended.

Desloratadine passes into breast milk, therefore the use of the drug "Aerius ®" for women who are breastfeeding is not recommended.

Children

There are limited data from clinical studies of the effectiveness of desloratadine tablets in adolescents aged 12 to 17 years. The efficacy and safety of using Aerius ® tablets under the age of 12 has not been established.

Drivers

In clinical studies, during which the ability to drive vehicles was assessed, no deterioration was found in patients taking desloratadine. However, patients should be advised that it is very rare that some people experience drowsiness, which can affect their ability to drive a car and complex equipment.

Overdose

In case of overdose, use standard measures to remove the unadsorbed active substance. Symptomatic and supportive treatment is recommended. In clinical studies in which desloratadine was administered in doses of 45 mg (which is 9 times the recommended), clinically significant adverse reactions were not observed. Desloratadine is not removed by hemodialysis; the possibility of its removal during peritoneal dialysis has not been established.

Side effects

In clinical studies for indications, including allergic rhinitis and chronic idiopathic urticaria, adverse effects were reported 3% more frequently in patients receiving a dose of 5 mg per day than in patients receiving placebo.

The most commonly reported side effects compared to placebo were fatigue (1.2%), dry mouth (0.8%) and headache (0.6%).

In clinical trials involving 578 adolescents aged 12 to 17 years, the most common side effect was headache (in 5.9% of patients taking desloratadine and 6.9% of patients receiving placebo).

Storage conditions

Store at a temperature not exceeding 30 ° C, in a dry place out of the reach of children.

Shelf life is 2 years.